Table 1.
Effects of MR16-1 on cancer-related symptoms in the LC-06-JCK mouse model
| 0 weeks | 5 weeks | ||||
|---|---|---|---|---|---|
| NTB | TB | NTB | TB | MR16-1 | |
| Body weight (g) | 25.5 ± 1.4 | 25.8 ± 1.3 | 28.0 ± 1.1 | 24.5 ± 2.0* | 25.9 ± 2.0** |
| Albumin (mg/mL) | 28.9 ± 3.0 | 26.5 ± 5.1* | 25.5 ± 3.8 | 16.7 ± 2.6* | 22.1 ± 2.8** |
| SAA (μg/mL) | 60.7 ± 95.7 | 589.2 ± 614.8* | 24.8 ± 12.7 | 5638.0 ± 2867.5* | 353.0 ± 302.9** |
| Tumor volume (mm3) | ND | 143.9 ± 43.0 | ND | 1369.9 ± 301.5 | 1647.6 ± 515.8 |
Body weight, serum albumin levels, SAA levels, and tumor volumes were measured in mice before treatment (0 weeks) and after being treated for 5 weeks. Results are the mean ± SD for 19–20 mice in each group. *P < 0.05, age-matched NTB group versus TB group (Wilcoxon test); **P < 0.05, TB group versus MR16-1 group (Wilcoxon test)